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Effect of blockade of angiotensin II on blood pressure,
renin and aldosterone in cirrhosis
EDWARD T. SCHROEDER, GUNNAR H. ANDERSON, STEPHEN H. GOLDMAN and DAVID H. P.
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Nephrology and Endocrinology Sections, Department of Medicine, Upstate Medical Center, State University of New York,
Syracuse, New York
Effect of blockade of angiotensin II on blood pressure, refill and
aldosterone in cirrhosis. l-Sar-8-ala angiotensin II (saralasin) was
infused intravenously in graded doses of from 0. Ito 10 ,.ig/kg/min
to five patients with cirrhosis and ascites after three days of re-
stricted sodium intake. In each patient blockade of All by sarala-
sin produced a marked fall in blood pressure, a rise in plasma renin
activity (PRA) and plasma renin concentration (PRC) and, in four
of the five, a fall in plasma aldosterone (PA). The rise in PRA and
PRC correlated poorly with changes in blood pressure. The effects
of saralasin rapidly reversed after cessation of the infusion. Plasma
volume was normal or high in each case. Three patients were
mildly hypotensive in the control state, and all five were resistant to
the pressor effect of infused All. After three days of salt loading,
the above effects of saralasin were diminished but not abolished, in
four normal subjects, after salt depletion, saralasin infusion in-
duced qualitatively similar but much smaller changes in blood
pressure, PRA and PRC. In two cirrhotic patients without ascites,
after salt depletion, saralasin infusion caused a rise in blood pres-
sure with no significant changes in PRA, PRC or PA. These results
provide evidence that in patients with cirrhosis and ascites circulat-
ing All is active in support of blood pressure, in direct suppression
of renal renin release, and in stimulation of aldosterone release.
Effets du blocage de l'angiotensine II sur Ia pression artérielle,, 'Ia
refine et l'aldostérone au cours de Ia cirrhose. La l-sar-8-ala angio-
tensine II (saralasine) a été administrée par voie intra-veineuse a
doses croissantes de 0,1 a l0jsg/kg/min a cinq malades atteints de
cirrhose ascitique après trois jours de restriction des apports de
sodium. Chez tous les malades le blocage de l'A II par Ia sara'lasine
determine une baisse importante de Ia pression artérielle, une
augmentation del'activité rCnine plasmatique (PRA) et de Ia
concentration plasmatique de rénine (PRC). Une baisse de
l'aldostérone plasmatique (PA) est observée chez quatre des cinq
malades. L'augmentation de PRA et PRC n'est pas bien corrélée
avec Ia baisse de Ia pression artérielle. L'effet de Ia saralasine est
rapidement reversible après Ia fin de Ia perfusion. Le volume
plasmatique dans chacun de ces cas était normal ou augmenté.
Trois de ces malades avaient un abaissement modéré de Ia pression
artérielle a l'état basal et tous les cinq étaient résistants a l'effet
presseur de l'angiotensine 11. Après trois jours de charge en sel les
effets de Ia saralasine décrits 'ci-dessus sont diminués mais non
abolis. Chez quatre sujets normaux déplétés en sel l'administràtion
de saralasine a produit des modifications quaiitativementsimilaires
mais très attCnuées en ce qui concerne Ia pression artérielie, PRA et
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PRC. Chez deux malades atteints de cirrhose 'sans ascite, déplétés
en sel, l'administration de saralasine determine une augmentation
de 'Ia pression artérielle sans modifications significatives de PRA,
PRC ou PA. Ces résultats apportent lapreuve'que chez les maiades
.atteints de cirrhoseet d'ascite l'angiotensine 11 circulante est active
dans Ic maintien de Ia pression artérielle, dans Ia suppression de Ia
liberation rénale de rénine et dans Ia stimulation de Ia liberation
d'aldostérone.
Patients with advanced cirrhosis and ascites may
have mild hypotension in the presence of normal or
high total plasma volume [1—5]. In such cases, de-
creased "effective." plasma volume and/or decreased
systemic vascular resistance have been suggested as
'causes of the low blood pressure [5]. Recent studies
using i.v. infusion of an angiotensin antagonist sug-
gest that in condictions with low plasma volume or
low 'cardiac output, maintenance 'of normal blood
pressure is dependent upon the vasoconstrictor effect
of circulating angiotensin II (All) [6, 7]. The purpose
of this study was to determine, by use of a specific
antagonist of All (the All analqgue l-sar-8-ala an-
giotensin II), whether the control of blood pressure in
patients with cirrhosis and ascites is angiotensin-de-
pendent. By assessment of changes in blood levels of
certain parameters of the renin-an'giotensin system in
response to blockade of circulating All, we also
sought to determine if a 'defective or inadequate re-
sponse of the renin-angiotensin system may be re-
sponsible in some patients for failure to maintain
blood pressure at a normal level.
Methods
Seven patients were selected from 'the medical wards
at the State University and the Vteran's Administra-
tion Hospitals, Syracuse, New York, and were studied
in the Clinical Research Center. Each had historical,
physical and laboratory evidence of chronic cirrhosis
of the liver, confirmed by biopsy in most cases, and
due to excessive alcohol intake in all but one case.
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Five patients (cases 1—5, Table 1) had moderate
to marked ascites with urinary sodium excretion
of less than 10 mEq per day. Two of these (cases 2
and 4) had evidence of hepatocellular dysfunction
with mild jaundice. Cases 6 and 7 had cirrhosis with-
out ascites. Each patient was medically stable at the
time of study, and none had intrinsic renal disease
or abnormal serum sodium, potassium, chloride,
calcium or bicarbonate concentration. In one patient
(case 1), observations were repeated after two months
during which general clinical improvement was noted.
All medications were discontinued on admission to
the Clinical Research Center and a constant diet
containing 10 mEq of sodium and 90 mEq of potas-
sium daily was started, with fluid ad lib. After three
to five days, the effects of an i.v. infusion of the an-
giotensin analogue were determined. Five of these
patients were then given a daily dietary supplement
of 150 to 190 mEq of Na as sodium chloride for three
days, resulting in an average weight gain of 2.1 kg.
Prior to a repeat infusion study, each patient was
given one to two liters of 0.9% sodium chloride i.v.
over a period of eight hours. After conclusion of the
second infusion study, diuretics were used to remove
excess fluid.
Infusion protocol. Upon waking, the patient ate
breakfast and remained in bed in a comfortable re-
cumbent position. Needles were inserted into veins
for infusion of the All analogue and for collection of
blood samples. Brachial artery systolic and diastolic
blood pressures were then recorded automatically ev-
ery two minutes by the Arteriosonde 1216 (Roche)
during a one-hour control period and during the i.v.
infusion of saralasin (1-sar-8-ala angiotensin II, Ea-
ton Laboratories) given initially at 0.1 g/kg/min. If
no significant change in mean blood pressure (10 mm
Hg or more) was noted after one hour, the rate was
increased to 1 tg/kg/min for one hour and then to 10
zg/kg/min for one hour. Blood samples were drawn
at the end of each hour and one hour following
discontinuation of the drug. Oral fluids were allowed
ad lib throughout the procedure. For comparison,
four normal volunteers were given an infusion of
saralasin as described above after three days of low
salt intake (10 mEq dietary Na per day). Some of the
data obtained from studies in these normal subjects
have been previously reported [8].
On each blood sample renin activity (PRA), renin
concentration (PRC), renin substrate and aldoste-
rone were measured. PRA was determined in dupli-
cate on each sample by radioimmunoassay of angio-
tensin I (Al) generated during incubation for two
hours using a modification of the method of Cohen et
al [9]. In our laboratory the mean SD for morning
samples taken from recumbent normal subjects was
5.3 + 0.44 ng/ml/hr after five days of low sodium
intake (10 mEq/day) and 1.0 + 0.1 ng/ml/hr after
three days of salt loading (150 mEq Na/day). PRC
was measured by a modification of the method of
Gould, Skeggs and Kahn [10]. Hog renin substrate
(Miles Laboratories) was added to plasma to obviate
possible effects of deficient endogenous substrate on
the in vitro generation of angiotensin. The Al ra-
dioimmunoassay was used to determine the amount
of Al generated after incubation for two hours at a
pH of 7.4. The mean + SD for morning samples from
recumbent normal subjects deprived of salt was 9.2 +
3.0 ng/ml/hr and salt-loaded normal subjects 1.3 +
0.7 ng/m I/hr. We chose to express values for PRC in
this study in terms of the Al generation rate rather
than in renin units because of multiple factors, possi-
bly independent of the plasma concentration of renin,
which might influence Al generation in this type of
assay [11]. Plasma renin substrate was determined by
the method of Tree [12] as modified by Waite, Tree
and McDermott [13] using the A! radioimmuno-
assay. The mean SD in our laboratory for normal
subjects deprived of salt and on no medication was
Table 1. Baseline data after salt deprivation in patients with cirrhosis
Patient
Blood
pressure,
mm Hg
Plasma Plasma
renin renin
activity, content,
ng/ml/hr ng/ml/hr
Plasma
renin
substrate,
moles/liter
Plasma
aldosterone,
ng/IOO ml
Angioterisin
11
sensitivity,
ng/kg/min
1la
2
3
4
5
6
7
Normalsubjects;
100/65
115/70
105/70
95/60
110/45
100/65
115/70
112/65
Mean sn
14 41
4 8
14 77
10 30
3 26
18 57
1 6
3 8
5.3 0.44 9.2 + 3.0
0.21
0.23
0.0
0.29
0.27
0.73
0.21
0.27
1.26 0.56
50
60
106
118
55
159
12
33
21.1 + 8.3
47
—
54
28
—
48
7
II
< 12
Case Ia represents a repeat study in case I after a two-month interval.
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1.2 0.56 tmole/1iter. Plasma aldosterone was de-
termined by the radioimmunoassay method of Under-
wood and Williams [14]. The mean + SD for salt-
deprived normal subjects recumbent at 8 to 9 AM
was 21.1 8.3 ng/l00 ml.
The pressor response to graded i.v. infusion of All
(l-asp-5-val angiotensin II, Ciba) was determined in
six of the seven patients in the salt-deprived state. The
rate of All infusion required to raise the diastolic
blood pressure 20 mm Hg was recorded as a measure
of the All sensitivity. In our laboratory, the All sensi-
tivity in salt-deprived normal subjects was less than
12 ng/kg/min.
Mean blood pressure was calculated as:
diastolic pressure + (systolic pressure — diastolic pressure)
3
These studies were approved by the Committee for
the Protection of Human Subjects of the Upstate
Medical Center. Prior to study, fully informed con-
sent was obtained from each patient. A physician and
nurse were in attendance at the bedside throughout
the study.
Results
Selected baseline data obtained after salt depriva-
tion and just prior to the infusion test are summa-
rized in Table 1. In patients with ascites the baseline
blood pressure was somewhat low, only case la hav-
ing a systolic pressure greater than 110 mm Hg. The
baseline PRA was high in four and PRC was high in
five of the six patients with ascites, and plasma al-
dosterone was elevated in each patient with ascites.
Plasma renin and aldosterone were within normal
limits in the two patients without ascites. Plasma
renin substrate was low in six of the seven patients. In
patients tested for response to All infusion, those
with ascites were resistant to the pressor effect of All,
whereas those without ascites were normally sensitive
to Al!. Renal function, as estimated by 24-hr clear-
ance of creatinine, was normal in four patients but
somewhat decreased (70 to 75 mI/mm) in three
patients with ascites. In five of the cirrhotic patients,
after salt deprivation, plasma volume using '251-la-
beled serum albumin ranged from 48 to 70 mI/kg dry
weight (weight minus estimated weight of ascitic
fluid). This compares to a range for plasma volume
from 39 to 49 mI/kg in normal subjects on salt-re-
stricted diet in our laboratory. Cardiac output, meas-
ured by '251-RISA dilution in one patient (case 5)
after salt deprivation, was 7.07 liters/mm with a pre-
dicted output of 6.26 liters/rn in.
The maximum change in blood pressure in re-
sponse to infusion of the All analogue is shown in
Fig. 1. In the salt-deprived state (Fig. IA) the All
analogue caused a fall in blood pressure in all six
studies in patients with ascites. The average of the
mean blood pressures in this group fell from a base-
line value of 77 mm Hg to 58.3 mm Hg. In patients I,
3 and 5, the minimum recorded blood pressure was
reached at an All analogue infusion rate of only 1.0
ig/kg/min, and in cases 1 and 3 the onset of hypo-
tension was precipitous and this dose level was not
exceeded. By comparison, in four normal patients
similarly salt-deprived, the maximum fall in mean
Fig. 1. Response of blood pressure to infusion of the All analogue 1-
sar-8-ala angiotensin 11 in patients with cirrhosis. A. After salt
deprivation. B. After salt repletion. (Shaded area defines the range
for four normal subjects.)
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pressure at a dose of 10tg/kg/min averaged only 5.2
mm Hg. In the two patients with cirrhosis but no
ascites (cases 6 and 7), baseline levels of blood pres-
sure, PRA, PRC and plasma aldosterone were nor-
mal, and the blood pressure rose in response to the
All analogue.
After salt repletion (Fig. 1B) four of five patients
with cirrhosis and ascites showed a definite fall in
mean blood pressure (ranging from 7 to 13 mm Hg)
in response to infusion of the All analogue at a rate
of 10 g/kg/min. This is in sharp contrast to the rise
in blood pressure noted in four normal subjects re-
ceiving high salt intake. In cirrhotics salt repletion
reduced the sensitivity of the blood pressure to the
All analogue, in that doses of 1.0 g/kg/min failed
to affect the mean pressure. Case 5, who was quite
sensitive to the analogue when salt-deprived, showed
no significant change in blood pressure during in-
fusion of the All analogue at a rate of 10 tg/kg/min
after salt repletion.
In most cases where blood pressure was altered by
the All analogue, return to baseline levels occurred
usually within 15 mm after the drug was stopped.
There was no significant change in pulse rate or
rhythm in any patient throughout the study, and
patients experienced no symptoms during infusion of
the All analogue.
Figures 2 and 3 show the effects of infusion of the
All analogue on PRA and PRC. In salt-deprived
patients (Figs. 2A and 3A) a definite increase in PRA
and PRC was noted during infusion of the analogue
in most patients. Following salt repletion, increases in
PRA and PRC of a similar nature were noted (Figs.
2B and 3B). In patients 6 and 7 no significant change
in PRA or PRC occurred during infusion of the
analogue (Figs. 2A and 3A). In six of eleven studies in
the patients with ascites, a significant increase in PRA
(50% or more above control values) occurred at in-
fusion rates of the analogue which produced no
change in mean blood pressure or only a slight de-
crease (3 mm Hg or less). Also in six of these eleven
studies, the peak plasma renin level appeared during
the first hour at an infusion rate of 0.1 tg/kg/min. In
contrast, none of the normal subjects showed a
change in PRA at this dose level. Thus, the effect of
the All analogue on plasma renin correlated poorly
with changes in blood pressure and was considerably
more potent in some patients with cirrhosis and as-
cites than it was in normal subjects.
Plasma renin substrate was measured before, dur-
ing and after infusion of the analogue, and there was
no change from the baseline value in any case.
Plasma aldosterone level (Figs. 4A and 4B) fell during
infusion of the All analogue in seven of twelve cases,
while in cases 6 and 7 (Fig. 4A) levels were initially
within the normal range and showed no definite
change during infusion. Changes were variable in
three studies.
Fig. 2. Response of plasma renin activity to infusion of the All
analogue I-sar-8-ala angiotensin 11 in patients with cirrhosis. A.
After salt deprivation. B. After salt repletion. (Shaded area defines
the range for four normal subjects.)
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Discussion
In certain types of hypertension associated with
high plasma renin activity there is indirect evidence
linking the elevation in blood pressure with circulat-
ing angiotensin II (All) [15—18]. Recently, evidence
has been obtained suggesting that this potent vaso-
constrictor may be important in maintaining normal
blood pressure under certain conditions. In salt-de-
pleted dogs and in dogs with low cardiac output due
to ligation of the thoracic inferior vena cava, i.v. in-
fusion of the specific antagonist of All used in the
present studies, 1-sar-8-ala angiotensin 11 (saralasin),
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Fig. 3. Response of plasma renin concentration to infusion of the All
analogue 1-sar-8-ala angiotensin II in patients with cirrhosis. A.
After salt deprivation. B. After salt repletion. (Shaded area defines
the range for four normal subjects.)
The statistical significance of the changes induced
by saralasin in patients with ascites was determined
using two-way analysis of variance. In the salt-de-
pleted state, changes were significant for blood pres-
sure and PRA (P < 0.005) and for PRC and aldoste-
rone(P <0.01). After salt repletion, changes in blood
pressure and PRA were significant (P < 0.01) but
changes in PRC and aldosterone were not.
Figures 5 and 6 show in a more detailed manner
results during representative studies (case 5) in the
salt-deprived and salt-repleted states.
1a40
Pre All Post
B. Analogue
Fig. 4. Response of plasma aldosterone to infusion of the All Una-
logue 1 -sar-8-ala angiotensin II in patients with cirrhosis. A. After
salt deprivation. B. After salt repletion.
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ation rate [10, 11, 28—30]. Plasma renin substrate was
Hours low in all but one of our patients. Although its forma-
tion and/or release may be increased by All [31, 32],
____________ ['
in the short period of our study we found no change
in substrate levels resulting from All blockade. We
rI
did not measure blood All in this study. However,
Kondo et al [33] have reported high blood All levels
_____
I in patients with cirrhosis and ascites, and they also
found direct correlation between blood All and
Fig. 5. Results of a representative study of infusion of the All
analogue I -sar-8-ala angiotensin II in a patient with cirrhosis and
ascites after salt deprivation. Shading in the bars corresponds to
rates of infusion of the analogue.
I I I I I
n
. nHFi.I[1
Fig. 6. Results of a representative study of infusion of the All
analogue I .sar-8-a/a angiolensin II in a patient with cirrhosis and
ascites after salt repletion. Shading in the bars corresponds to rates
of infusion of the analogue.
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Thus, a blood level of All possibly insufficient to
maintain normal blood pressure in an angiotensin-
dependent patient may be sufficient to suppress renin
release, and may prevent maximum generation of All
in response to the stimulus of hypotension.
It would be of interest to know the actual level of
circulating All in these patients particularly consid-
ering that low plasma renin substrate concentration
in cirrhotic patients may affect angiotensin gener-
100
80
o
a,E 40
20
0.1 1.0 10.0
A II analogue, pg/kg/rn/n
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PRA. Thus, the elevated baseline PRA found in
many of our patients is consistent with high blood
All levels. Whether or not the All level was appro-
priate to the stimulus of hypotension in our patients
is not clear.
The resistance to the pressor effect of i.v. adminis-
tered All noted in our angiotensin-dependent pa-
tients may also be indirect evidence of high am-
bient blood All levels, since in several animal models
All resistance has been attributed to saturation of
All receptors by endogenously generated All [6, 7,
34]. This may be the cause of the marked resistance to
All previously noted in cirrhosis [35]; however, our
study does not address itself to this question.
Saralasin effectively blocked aldosterone release
and/or synthesis in four of five salt-deprived patients
who had elevated baseline serum aldosterone levels,
in spite of increased PRC and PRA (Fig. 4A). Thus,
in cirrhotic humans, as in dogs with plasma volume
depletion or low cardiac output [6, 7], aldosterone
secretion is sensitive to blockade by the octapeptide
analogue, l-sar-8-ala ALL, even though a heptapep-
tide metabolite of All may contribute to stimulation
of aldosterone secretion [36—38].
The physiological and hormonal responses to All
blockade in our patients with cirrhosis and ascites
noted above were similar in evety way to those of
animal models with plasma volume depletion or low
cardiac output [6, 7]. Since plasma volume was nor-
mal or high in our patients and presumably cardiac
output was adequate [2—5], the concept of deficient
"effective" plasma volume might be proposed as an
explanation for angiotensin dependency of blood
pressure in cirrhosis with ascites. The salt load given
to our patients may have been inadequate to restore
"effective" plasma volume to normal and to normal-
ize their response to All blockade. Deficient "effec-
tive" plasma volume, however, cannot explain the
decreased systemic resistance noted in some cirrhotic
patients with hypotension [2—5]. In addition, al-
though the sensitivity of blood pressure to All block-
age was decreased following salt repletion, it is not
clear whether this was due to plasma volume expan-
sion or to a direct action of sodium ion on vascular
smooth muscle cells or on All vascular receptors
[39, 40].
In summary, these studies provide evidence that in
patients with cirrhosis and ascites, circulating All
plays an important role in support of blood pressure,
in maintenance of plasma aldosterone level, and in
direct suppression of renal renin release. These effects
are apparently influenced by the state of sodium bal-
ance, and they were not demonstrable in patients
with cirrhosis but without ascites. The dependency
upon All for control of blood pressure in these
patients is probably a normal compensatory mecha-
nism in response to some derangement of fluid or
hemodynamic balance. The data obtained from these
preliminary studies do not allow for definitive con-
clusions concerning the possible role of a defective
response of the renin-angiotensin system in causing
low baseline blood pressure noted in some patients
with cirrhosis and ascites. The circulatory abnor-
malities in cirrhosis are probably multifactorial in
origin, and further studies of the effects of All block-
ade might contribute to a clearer understanding of
the role of the renin-angiotensin system in vasomotor
control in patients with cirrhosis. Since this study was
completed, however, it has come to our attention that
occasionally dogs with ligation of the thoracic vena
cava may be very sensitive to All blockade. In a study
of one such animal under anesthesia, infusion of sa-
ralasin in a dose of 6 tg/kg/min resulted in profound
hypotension and death within ten minutes [personal
communication, James 0. Davis]. Because of phys-
iological similarities between this dog model and
patients with cirrhosis and ascites, it might be antici-
pated that some patients with cirrhosis and ascites,
particularly when depleted of salt, might be extremely
sensitive to blockade of AU by saralasin.
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